SeekingAlpha  Jan 10  Comment 
By Zacks Investment Research: AFFX's preliminary revenue guidance for the fourth quarter came in ahead of expectations, sending the earnings estimates higher and the stock back to Zacks Rank #1 (Strong Buy) on January 8, 2014. About the...
Benzinga  Sep 19  Comment 
KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that Herb C. Cross will join the company as of September 23, 2013, and transition into the Chief Financial Officer role in coordination with Jeffrey H. Cooper, the company's current CFO. The...
Benzinga  Jun 7  Comment 
As previously announced, on May 28, 2013, Affymax, Inc. (OTC: AFFY) received a determination letter (the “Determination Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) delisting the Company's common stock from...
Benzinga  Jun 3  Comment 
Synta Pharmaceuticals (NASDAQ: SNTA) shares dipped 32.93% to $4.95 after the company reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of ganetespib in second-line non-small cell lung cancer. Infinity Pharmaceuticals...
Benzinga  Jun 3  Comment 
StreetInsider.com  Jun 3  Comment 
Affymax, Inc. (Nasdaq: AFFY) 31.3% LOWER; to End Supply Agreement with Lonza; Has No Plans to Appeal Nasdaq Delisting Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) 17.4% LOWER; announced updated Phase 1 data from an ongoing study of IPI-145, its...
StreetInsider.com  May 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Affymax+%28AFFY%29+Has+No+Plans+to+Appeal+Nasdaq+Delisting/8382958.html for the full story.
StreetInsider.com  May 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Affymax+%28AFFY%29+to+End+Supply+Agreement+with+Lonza+/8382783.html for the full story.
StreetInsider.com  May 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Affymax+%28AFFY%29+CEO+to+Be+Replaced+by+Rep+of+Restructuring+Firm/8338007.html for the full story.
StreetInsider.com  May 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Affymax++%28AFFY%29+Reports+Q1+Loss+of+%240.71/8324472.html for the full story.
StreetInsider.com  May 8  Comment 
TORM (Nasdaq: TRMD) 70.4% HIGHER; in part, reported Q1 EBITDA of $36 million, from a negative $7 million reported in the same period last year. Affymax, Inc. (Nasdaq: AFFY) 34.8% HIGHER; continuing higher as earnings for the company are expected...

You may also be interested in articles related to Affymax (AFFY):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki